🇺🇸 FDA
Patent

US 7256294

Crystalline form of a benzimidazole-carboxamide medicinal compound

granted A61PA61P1/00A61P1/10

Quick answer

US patent 7256294 (Crystalline form of a benzimidazole-carboxamide medicinal compound) held by Theravance, Inc. expires Mon Aug 09 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Aug 14 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 09 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P1/00, A61P1/10, A61P1/14